GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Additional Paid-In Capital

ANL (Adlai Nortye) Additional Paid-In Capital : $438.71 Mil(As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Additional Paid-In Capital?


Adlai Nortye's quarterly additional paid-in capital increased from Jun. 2023 ($6.42 Mil) to Dec. 2023 ($438.71 Mil) but then stayed the same from Dec. 2023 ($438.71 Mil) to Jun. 2024 ($438.71 Mil).

Adlai Nortye's annual additional paid-in capital stayed the same from Dec. 2021 ($6.42 Mil) to Dec. 2022 ($6.42 Mil) but then increased from Dec. 2022 ($6.42 Mil) to Dec. 2023 ($438.71 Mil).

Adlai Nortye Additional Paid-In Capital Historical Data

The historical data trend for Adlai Nortye's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Additional Paid-In Capital Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
6.42 6.42 438.71

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial 6.42 6.42 6.42 438.71 438.71

Adlai Nortye Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Adlai Nortye Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Additional Paid-In Capital
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.